FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma

Purpose To elucidate the prognostic role of post-therapeutic 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET), we conducted a retrospective cohort study analysing the clinical factors that affect overall survival after non-operative therapy for unresectable hepatocellular carci...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2010-03, Vol.37 (3), p.468-482
Main Authors: Higashi, Tatsuya, Hatano, Etsuro, Ikai, Iwao, Nishii, Ryuichi, Nakamoto, Yuji, Ishizu, Koichi, Suga, Tsuyoshi, Kawashima, Hidekazu, Togashi, Kaori, Seo, Satoru, Kitamura, Koji, Takada, Yasuji, Kamimoto, Shinji
Format: Article
Language:English
Subjects:
Adult
Aged
Analysis of Variance
Biological Transport
Cancer
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - surgery
Carcinoma, Hepatocellular - therapy
Cardiology
Female
Fluorodeoxyglucose F18 - metabolism
Humans
Imaging
Liver diseases
Liver Neoplasms - diagnosis
Liver Neoplasms - pathology
Liver Neoplasms - surgery
Liver Neoplasms - therapy
Male
Medical prognosis
Medicine
Medicine & Public Health
Middle Aged
Nuclear Medicine
Oncology
Original Article
Orthopedics
Positron-Emission Tomography
Prognosis
Radiology
Retrospective Studies
Survival Rate
Time Factors
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To elucidate the prognostic role of post-therapeutic 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET), we conducted a retrospective cohort study analysing the clinical factors that affect overall survival after non-operative therapy for unresectable hepatocellular carcinoma (HCC). Methods Sixty-seven cases with unresectable HCC who received non-operative therapy (transcatheter arterial chemoembolization: n  = 24, transcatheter arterial infusion chemotherapy: n  = 31, radiofrequency ablation: n  = 5 or systemic chemotherapy: n  = 7) and had received FDG PET for the evaluation of the therapeutic effect within 1 month after the end of the therapy were evaluated. Overall survival rate was evaluated using the univariate and multivariate analyses of relevant clinical and laboratory parameters before and after therapy, including visual PET analysis and quantitative analysis using maximum standardized uptake value (SUV). Results Visual PET diagnosis of post-therapeutic lesions was a good predictor of overall survival of unresectable HCC patients. The low FDG group showed significantly longer survival (average: 608 days) than that (average: 328 days) of the high FDG group ( p  
ISSN:1619-7070
1619-7089
DOI:10.1007/s00259-009-1284-9